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ABSTRACT
Many pathogenic bacteria use their iron acquisition mechanisms to live inside hosts.
Streptococcus pyogenes is a pathogenic bacterium that uses streptococcal iron acquisition ABC
transporter to obtain heme. SiaA (HtsA, spy1795), a lipoprotein located on the cell surface,
serves as a heme binding protein. To understand the iron-uptake mechanism, histidine 229, one
of the two proposed axial ligands in SiaA, was mutated to alanine. SiaA H229A was expressed in
E. coli, lysed by French Press, and purified by fast protein liquid chromatography (FPLC). SDSPAGE indicated that pure protein was isolated. Nickel affinity FPLC gave purer H229A when
0.5 M imidazole was added to the binding buffer. Overall, histidine 229 is likely to be an axial
ligand in wild type SiaA, as shown by the fact the mutant readily lost heme as evidenced by UVvis spectra.
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1
Introduction
Many pathogenic microorganisms use iron acquisition mechanisms to obtain
heme. Heme is an essential iron source for many bacteria (Crosa et al., 2004). An
understanding of the structure and mechanism of the iron uptake pathways may help in
the design agents to control these pathways, possibly resulting in new clinical agents to
treat disease.
S. pyogenes uses SiaABC to acquire heme from its host. SiaA, a heme binding
protein, is a lipoprotein located on the cell surface. We have proposed that methionine 79
and histidine 229 are the two axial ligands of the heme. In this project, histidine 229 was
studied. The native ligand, in wild type SiaA, His229, was mutated by replacing histidine
with alanine (H229A). H229A SiaA was expressed, purified, and studied.

Streptococcus pyogenes. Streptococcus pyogenes (Group A Streptococcus) is a Grampositive, non-motile, non-spore-forming coccus (Bates et al., 2005; Bates et al., 2003; Liu
& Lei, 2005). It is a facultative anaerobe. S. pyogenes has a capsule composed of
hyaluronic acid and exhibits beta (clear) hemolysis on blood agar (Cunningham, 2000).
It can colonize the respiratory tract, bloodstream, and the skin. It causes severe infections
such as pharyngitis (strep throat), toxic shock syndrome, necrotizing fasciitis (flesh eating
bacteria), and rheumatic fever.
S. pyogenes exhibits iron-dependent growth (Eichenbaum et al., 1996b). Iron
limitation leads to the induction of genes encoding a putative iron transport system,
hemolysins, a putative superoxide dismutase, a bacterioferritin homologue, and iron
dependent repressors (Bates et al, 2005). S. pyogenes produces iron acquisition proteins
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(siderophores, hemophores, or specific receptors) to obtain more iron when the
concentration is limited (Bates et al, 2003). The bacterium cannot extract iron from
transferring or lactoferrin (Eichenbaum et al., 1996a; Eichenbaum et al, 1996b).
Heme or hemoglobin is an essential iron source in vivo (Bates et al, 2003; Bates
et al, 2005). Studies in an iron-depleted medium experiment showed that heme in sheep
blood aided S. pyogenes growth. S. pyogenes can also extract heme from myoglobin,
heme-albumin, haptoglobin-hemoglobin complexes, and hemopexin:hemoglobin
complexes. S. pyogenes utilizes surface receptors to bind hemoglobin and other
hemoproteins (Bates et al, 2003).

SiaABC. S. pyogenes use SiaABC to acquire heme (Figure 1) (Bates et al, 2003; Bates
et al, 2005; Liu et al, 2005). SiaABC is the streptococcal iron acquisition ABC
transporter (Bates et al, 2003; Bates et al, 2005). Another name for SiaABC is HtsABC,
the heme transporter of group A streptococcus (Liu & Lei, 2005). The SiaABC
(HtsABC) is made up of three genes in a ten gene cluster: spy1793, spy1794, and
spy1795 (Bates et al, 2003; Lei et al., 2003). SiaA (HtsA, spy1795) is a lipoprotein
located on the cell surface and serves as a heme binding protein. SiaB (HtsB, spy1794) is
the membrane permease. SiaC (HtsC, spy1793) is the ATPase that is uses the energy of
ATP for heme import.

SiaA. SiaA binds both hemoglobin and heme (Bates et al, 2003; Lei et al, 2003; Liu et
al, 2005). A recombinant form of SiaA (rSiaA) was constructed in which the lipoprotein
tail of SiaA at the N-terminus was replaced with a His-tag Xpress epitope (Figure 2)
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(Bates et al, 2003). Western blot and SDS-PAGE showed that the recombinant protein
bound hemoglobin. Enterokinase (EK) cleavage and hemoglobin-binding assays showed
that rSiaA both with and without His-Xpress epitope were able to bind hemoglobin.
In the binding assay experiment, transferrin served as a control and did not bind
hemoglobin (Bates et al, 2003). A solid phase binding assay showed that SiaA could
form a stable complex with hemoglobin but it could not bind myoglobin or hemoglobinhaptoglobin complexes. However, it can acquire iron from these species, indicating that
S. pyogenes needs additional proteins to take up heme and transport it to SiaA
(Eichenbaum et al, 1996b).
When SiaA was expressed and purified in E. coli, the sample shows an intense red
color (Bates et al, 2003; Lei et al, 2003; Liu et al, 2005). This was due to the presence of
heme in the heme-binding protein. The UV-visible absorption spectrum for SiaA showed
peaks at 275, 370, 417, 530, and 560 nm (Lei et al, 2003). The SDS-PAGE indicated
that SiaA was about 35 kDa (Bates et al., 2003; Lei et al., 2003; Liu & Lei, 2005). As
isolated, recombinant SiaA contained about 0.25 bound heme molecule, whereas
reconstituted SiaA contained about 1.0 bound heme molecules (Liu et al, 2005).

ABC Transporters. ATP-binding cassette (ABC) proteins are multi-domain structures
that use the energy of ATP hydrolysis to translocate solutes across cellular membranes
(Figure 3) (Jones & George, 2004; Jones & George, 2005). ABC transporters are made
up of two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs).
The TMDs act as the substrate binding sites, while the NBDs, molecular motors, use ATP
energy for conformational change to transport the solutes (Jones et al, 2004). The TMDs
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contain multiple hydrophobic segments. They consist of α-helices that form six to eleven
membrane spanning regions and form the transmembrane channel. These TMDs are
substrate-specific. They connect to an intra-cytoplasmic helix bundle, which interacts
with the NBDs.
The NBDs are located in the cytoplasm (Jones et al, 2004). They contain Walker
A and B motifs and a highly conserved (C) motif known as the “LSGGQ” motif. The
Walker A and B motifs are consensus sequences for nucleotide binding. They are
separated by approximately 90 – 120 amino acids. The Walker A motif (G-X-X-G-X-GK-S/T) is a phosphate binding (P) site consisting of a glycine loop followed by an
uncapped α-helix. Its function is to bind the nucleotide through electrostatic interactions
with the triphosphate moiety. The Walker B motif contains four hydrophobic residues
and an aspartate. The Walker B motif consists of a ß strand within the core of the
nucleotide-binding fold. To maintain the geometry of the active site, the Walker B
aspartate hydrogen bonds to ligands coordinated to the catalytic Mg2+ ion. The C motif is
the signature sequence of ABC transporters. It is located after the Walker B sequence.
ABC transporters are found in both prokaryotes and eukaryotes (Jones et al,
2004). They are mostly unidirectional. Eukaryotes use ABC proteins as exporters while
prokaryotes use them as importers. In prokaryotes, the Gram-negative ABC protein is a
periplasmic binding protein dependent transporter (Higgins, 1992; Higgins & Linton,
2001; Higgins, 2001). The Gram-positive ABC protein is a binding lipoprotein
dependent transporter. The importers have four polypeptide subunits (two TMDs and
two NBDs) and accessory periplasmic binding proteins (PBPs). In general, each ABC
transporter has a PBP fused to each TMD, meaning that there are two substrate transfer
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sites at the PBP-TMD interfaces. Eukaryotes exporter do not have PBPs. The exporters
are made up of a single polypeptide with the TMD connected to the C-terminal end of
each NBD. The ABC importers contain TMDs that range from 8 to 20 transmembrane
helices (Locher, 2004). The ABC exporters TMDs have a total of 12 transmembrane
helices.
The TMDs and NBDs are organized in the order NH3+-TMD-NBD-TMD-NBDCOO- for a full transporter (Higgins, 1992; Higgins, 2001; Higgins et al, 2001).
Sometimes, half-transporters are present in both prokaryotes and eukaryotes. Halftransporters are comprised of one TMD and one NBD. Each TMD is covalently fused to
a C-terminal NBD. Otherwise, each TMD is initially fused to an N-terminal NBD then
followed by a TMD (Jones et al, 2004). Half-transporters can be homodimers or
heterodimers.

The cobalamin ABC transporter: BtuCDF. Btu (B twelve uptake) is an E. coli protein
assembly that imports vitamin B12 (Karpowich et al., 2003). Btu includes the ABC
transporter BtuCD, the periplasmic binding protein (PBP) BtuF, and the outer membrane
transporter BtuB. In the BtuCD, there are two copies of the membrane-spanning BtuC
subunit (Locher & Borths, 2004). There are also two copies of the BtuD subunits which
are the nucleotide binding domains. The BtuC and BtuD subunits form a functional
heterotetramer (BtuC2D2). On the interface of the BtuC2 subunits, two pairs of helices in
an anti-parallel arrangement form a single translocation pathway. The pathway has a
cavity that opens to the periplasmic space and allows the corrin ring of vitamin B12 to fit.
After binding vitamin B12, the residues in two loops of the cavity are closed to the
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cytoplasm. On the cytoplasmic side, the BtuD subunits are aligned such that the
nucleotide is bound at the dimer interface. The ATP molecule binds against the P-loop of
the opposite subunit. Locher speculates that the membrane spanning BtuC subunits keep
the BtuD subunits properly aligned through extensive interdomain interactions (Locher
et al, 2004). After hydrolysis, the conformational changes from ATP binding are
transmitted through various loops in the conserved NBD region to the BtuC subunit
(Borths et al., 2002). Locher has proposed that the amino acid residues of the BtuD
subunits involved in the interface with BtuC are clustered around the Q-loop (Locher et
al, 2004). The Q-loop acts as a λ-phosphate sensor, which changes the conformation upon
nucleotide binding and hydrolysis.

BtuF. BtuF binds vitamin B12 and releases it to BtuCD channel (Figure 4) (Borths et al,
2002; Locher et al, 2004). BtuF consists of two globular (α/ß) domains connected by a
rigid α-helix, α-6 (Karpowich et al, 2003). Between the two domains, a deep cleft is
formed, which is the substrate binding site. Each globular domain has a secondary
structure that alternates between α-helixes and parallel β–sheets at the N-terminus.
Domain I starts at the N-terminus, while domain II starts at the C-terminus. Both domains
are α/ß sandwiches. Domain I consists of five-stranded parallel ß-sheet with α-helix
connected to each strand. Its α-5 helix lies against the interdomain α-6 helix to form a
partial helical bundle, which contacts the B12 at its dimethylbenzimidazole (DMB) and
propionamide groups. Domain II consists of a four stranded parallel ß-sheet with
connecting α-helix. Instead of α-5 helix, the C-terminal helix (α-11) packs against the
interdomain α-6 helix.
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The B12 binding site of BtuF is acidic while the protein itself is basic (Karpowich
et al, 2003). About 60% of the B12 is inside the binding cleft, held in by 11 residues that
make direct contacts with B12 in both of the crystal structure monomers. Domain I
contacts B12 50 times with six residues while domain II uses 5 residues to contact B12 39
times.

Iron acquisition in bacteria. Many pathogenic bacteria use their iron acquisition
mechanisms to live inside hosts. Iron acquisition is necessary because free iron is an
important nutrient factor for bacterial infection (Skaar & Schneewind, 2004). Although
humans have an abundant amount of iron, essentially all of it is bound, largely by
proteins. An iron limited environment is a hostile environment for the growth of bacteria
unless they have mechanisms to access these bound iron atoms. In humans,
hemoproteins (largely hemoglobin and myoglobin) contain the majority of iron atoms
(Mazmanian et al., 2003). Erythrocytes carry 60 – 75% of the body’s iron content in
hemoglobin. When erythrocytes lyse, hemoglobin is degraded and heme is released. Free
heme is not tolerated by cells. Hemopexin binds the free heme and transports it back to
the liver.

Staphylococcus aureus Isd System. S. aureus has an iron regulated surface determinant
(Isd) system which is capable of binding and transporting heme (Skaar et al, 2004).
There are two ways that S. aureus obtains both free heme and hemoproteins and uses
them as iron sources. One of these is through siderophore-dependent mechanisms.
These use an iron chelator that has a high affinity for iron to remove and transport iron

8
atoms from host proteins into the bacterial cell. Another way is through Isd gene
clusters, which are only transcribed when concentrations of iron atoms are low.
The Isd system of S. aureus consists of IsdA, IsdB, IsdC, IsdD, IsdE, IsdF, SrtB,
IsdG, IsdH, and IsdI (Figure 5) (Skaar et al, 2004; Skaar et al., 2004). These
transcriptional units are made up of cell-wall anchored surface proteins (IsdABCH), a
membrane transporter (IsdDEF), a sortase (SrtB), and two cytoplasmic proteins (IsdGI).
The IsdABCH, IsdDEF, and IsdGI are involved in binding heme, while sortase acts as an
enzyme to covalently attach specific proteins, to the cell wall.

Sortase-mediated cell wall anchoring pathway. Sortases, membrane anchored
transpeptidases, are enzymes that catalyze amide linkage formation between the cell wall
peptidoglycan and the C-terminus of a protein (Jonsson et al., 2003; Skaar et al, 2004).
These enzymes are also used to cleave LPXTG motifs of the protein. The LPXTG motif
is made up of five amino acids: leucine, proline, X, threonine, and glycine, where X is
any amino acid. The LPXTG motif, a hydrophobic region, and a tail of charged residues,
all located near the carboxyl terminal, are the three factors that are necessary for the
covalent adhesion between proteins and cell wall peptidoglycan (Paterson & Mitchell,
2004). They act as the cell wall sorting signal.
There are two types of sortases, sortase A and sortase B. Sortase A anchors the
LPXTG motif (IsdA, IsdB, and IsdH) of the Isd system to the bacteria cell wall (Jonsson
et al, 2003). Sortase A recognizes the LPXTG motif by detecting acidic residues and the
hydrophobic region of these three proteins (Skaar et al, 2004). Most of the time, sortase
A is active. When sortase A is inactivated, a covalent linkage between bacteria cell wall

9
and the protein cannot be established. Sortase A substrates are anchored to the
pentaglycine crossbridge of the staphylococcal cell wall; the inability to covalently
anchor the proteins to the cell wall affects bacterial virulence. Sortase B (srtB) anchors
isdCDEFsrtBisdG proteins, which are involved in binding heme, to the cell wall of the
bacteria.
The Isd proteins in sortase A and sortase B are under the regulation of the irondependent repressor Fur, a ferric-uptake regulator protein (Skaar et al, 2004; Jonsson et
al, 2003). Fur is a repressor gene that controls the production of Isd proteins (Maresso &
Schneewind, 2006). Fur functions as a regulator that senses and responds to the need to
acquire iron from the environment. When bacteria sense the exhaustion of iron, Fur
activates the production of Isd proteins. Sortase B, IsdA, IsdB, IsdC, and IsdH can then
be assembled to ensure successful nutrient acquisition.
Inactivation of sortases reveals that the Isd system has a role in uptake of heme
iron atoms into the bacteria (Skaar et al, 2004). With the inactivation of sortase A, the
level of heme iron in S. aureus is decreased due to the reduction of heme being
transported into the cell. As the result, S. aureus does not have the ability to bind to
hemoglobin as before and its virulence is diminished. Sortase B does not reduce bacteria
virulence greatly when it is inactivated. However, it reduces the persistent infection of S.
aureus in tissues. This is thought to be due to an inability to acquire heme iron atoms
from the host through the loss of IsdC anchoring.

Perisplasmic binding protein. Most PBPs contain two globular domains that are
connected by a hinge region (Eakanunkul et al., 2005). The pocket between the two
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domains forms the binding site. The PBP consists of three groups. Group I has three
interdomain connections, group II has two interdomain connections, and group III has
one interdomain connection (α-helical). The proteins BtuF and FhuD are part of group
III PBPs and sequence homology suggests that ShuT is also a Group III PBP.

ShuT. ShuT, a PBP, binds heme in Shigella dysenteriae (Eakanunkul et al, 2005). It
transports heme to the proteins ShuUV, which are a cytoplasmic permease and an
ATPase. The sequence of ShuT is similar to the sequences of BtuF and FhuD.
ShuT is a monomeric protein (Eakanunkul et al, 2005). SDS-PAGE and size
exclusion chromatography show that ShuT has a molecular weight of approximately 28.5
kDa. ShuT binds one b-type heme per monomer. Tyr94 is the only axial ligand. Tyr228
helps to stabilize the interaction between the ligand and ShuT; it does not directly interact
with heme iron.

FhuD. FhuD, a PBP, binds hydroxamate-type siderophores in E. coli (Clarke et al.,
2002b; Clarke et al., 2002a; Krewulak et al., 2005; Carter et al., 2006). It obtains
siderophores from FhuA, an outer membrane receptor, and transports them to FhuBC, the
inner membrane ATP-binding cassette transporter. FhuD has a molecular mass of 32
kDa. It has two distinct domains that are connected by a long α-helical backbone. The
N-terminal domain consists of five β-sheets and four α-helices while the C-terminal
domain has two β-sheets with three α-helices. The shallow pocket between the two
domains makes up the siderophore binding site. The pocket is hydrophobic and has
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aromatic residues. The movement of amino acid side chains in the binding cleft allows a
variety of hydroxamate-type siderophores to bind.
Siderophores bind to FhuD through both hydrophobic and hydrophilic
interactions (Clarke et al, 2002b; Clarke et al, 2002a; Carter et al, 2006). When the
siderophore binds, its methylene carbon atoms form hydrophobic interactions with
aromatic FhuD residues. There are three hydrogen bonds formed between albomycin and
FhuD. Two of the hydrogen bonds form between the hydroxamate and the FhuD residue
Arg84 while the other forms between the hydroxamate and Tyr106. Similar to the
albomycin binding, the interactions between gallichrome and FhuD also show hydrogen
bonding, except that there is an intermediate water molecule.

MntC. In C. synechocytis, MntC is the periplasmic binding protein for the manganese
(Mn2+) ABC transport system (Rukhman et al., 2005). MntC has two globular domains
connected by an α-helix. His89, His154, Glu220, and Asp295 are proposed to be the
ligands to the manganese. The metal ion-binding site is asymmetric in that the two
negatively-charged residues are located closer to the manganese ion than the two
histidine residues.
The crystal structure of MntC shows three monomers (A, B, and C) in the unit
cell (Rukhman et al, 2005). Each monomer has four domains: the N-terminal upper
globular domain, the α-helical backbone, the lower globular domain, and the C-terminal
domain.
MntC has a disulfide bond between Cys219 and Cys268 close to the surface
(Rukhman et al, 2005). Cys219 is located before Glu220, which binds Mn2+. The loop
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that contains Cys268 is in contact with the loop that contains Asp295, which also binds
Mn2+. Reduction of the disulfide bond lowers the affinity of MntC toward Mn2+.
Monomer C is more disordered that either A or B (Rukhman et al, 2005). Most
of the disordered region is localized in the lower domain. The disulfide bond in this
monomer has weaker electron density, which may indicate that the cysteine side chains
adopt a number of conformations. The poor electron density on Glu220 shows that this
residue is flexible. The electron density at the Mn2+ of monomer C is weaker than the
density at the Mn2+ of monomers A and B, indicating there is a lower metal ion
occupancy in this monomer. The Mn2+ binding site is also 0.5 Å further from Glu220
and closer to His89. Rukhman et al. propose that the disulfide bond in monomer C is
heterogeneous, with partial reduction leading to movements in the lower domain
(Rukhman et al, 2005).

HasA. HasA is an extracellular heme binding protein. It is secreted by bacteria; its
function is to bind heme and transport it to an outer membrane receptor. Most studies
have been performed on the protein from Serratia marcescens (Deniau et al., 2003;
Deniau et al., 2001). The crystal structure shows that the holoprotein is made up of four
α-helices and six β-sheets (Arnoux et al., 1999). The four α-helices are on the same side
of the protein. The two loops at the interface between the α-helices and the β-strands
hold the heme. The heme propionates point toward the solvent. With hydrophobic
binding pocket residues, heme binding maintains its stability through the help of polar
interactions. These include three hydrogen bonds that interact with propionate groups,
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two axial bonds, and a network of hydrogen bonds between the core of the protein and
residues of the binding pocket.
The axial ligands are histidine (H32) and tyrosine (Y75). Through hydrogen
bonding, asparagine (N41) and histidine (H83) residues are linked to the axial ligands.
Asparagine, glycine, and tyrosine (N34, G35, and Y137) residues are linked to heme
propionate groups.
The tyrosine (Y75) is bound to the heme iron with the bond length of 2.0 Å while
histidine (H32) is bound to the heme with the bond length of 2.32 Å. Studies of mutation
of Y75 (Y75A) suggests that H83 can replace Y75 in binding heme (Arnoux et al, 1999).
Although H83 does not directly bind the iron, evidence from thermodynamics
experiments show that H83 is the main factor in affecting the heme binding. When
alanine (H83A) or glutamine (H83Q) replaces histidine, the affinity of the heme binding
is reduced by 260 and 150 times, respectively. Comparing to the mutation of histidine
axial ligand (H32A), the mutation of H83 induces a higher loss of affinity. The
interaction of H83 with Y75 indicates that the hydrogen bonding enhances the
nucleophilic of Y75. It helps holding the tyrosine ring in the correct orientation so that
Y75 can bind to iron.

Campylobacter jejuni. Campylobacter jejuni is a rod-shaped, curved pathogenic
bacterium that causes food borne infection, especially diarrhea (Muller et al., 2006). C.
jejuni is a gram negative bacterium and is commonly found in animal feces. C. jejuni
needs iron (Fe) to survive.
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C. jejuni uses the enterobactin siderophore to take up iron (Muller et al, 2006).
Enterobactin is an iron chelator and consists of triscatechol (metal binding units) that are
linked via amides to a triserine ring (the backbone). Enterobactin chelates iron through
triscatechol ligands, forming a Δ configuration.
CeuE is a ferric enterobactin binding protein of C. jejuni (Muller et al, 2006).
CeuE is made up of α-helices and β-strands; the majority of the protein consists of αhelices. Two α-helices span the protein, while six β-strands are located at one end of the
protein and seven are located at the other.
Enterobactin binds iron, forming a ferric-enterobactin complex (FeEnt)
(Raymond & Dertz, 2004) (Raymond et al., 2003; Raymond et al, 2004). A cell surface
receptor protein recognizes the FeEnt and transports it into the periplasm. Subsequently,
the periplasmic binding protein, CeuE, binds the FeEnt and transfers it to a membranebound protein that transports it to the cytoplasm.
H6-mecam is one of the synthetic tris-catecholamide ligands that mimic
enterobactin (Muller et al, 2006). CeuE recognizes H6-mecam through a combination of
the α-helices, β-strands, and loops. There is no direct binding between iron and the
protein. The residues closest to the H6-mecam are Arg249, Tyr288, Arg205, Arg118, and
Lys121.
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Materials and Methods:

Homologous structure: 3D-JIGSAW. The sequence of wild type SiaA was submitted
to the 3D-JIGSAW website (http://www.bmm.icnet.uk/servers/3djigsaw/). The
homologous structures for BtuF (1N4D) were selected. The graphical coordinates of the
homology models (starting with the line ATOM 1) were saved as a txt file. The file was
renamed as a pdb file and opened with Rasmol 2.7.2.2.2.1 (originally developed by Roger
Sayle).

Homologous structure: LOOPP. The sequence of wild type SiaA was submitted to the
LOOPP website (http://cbsuapps.tc.cornell.edu/loopp.aspx). The homologous structures
for BtuF (1N4A), CeuE (2CHU), and FhuD (1K7S) were selected. The graphical
coordinates of the homology models (starting with the line ATOM 1) were saved as pdb
files and opened with Rasmol.

General. UV-vis spectra were taken on a 50-Bio (Varian, Palo Alto, CA) UV-visible
spectrophotometer. Water (18.2 MΩ) was from a NANOpure DiamondTM water purifier
(Barnstead International, Dubuque, IA). The H229A mutant was a gift of Dr. Zehava
Eichenbaum (2aH XUB LB-AMP), stored in a cryovial at -80 °C.

Preparation of Luria-Bertani media. Luria-Bertani (LB) media (2 L) was prepared
with 20 g BactoTM Tryptone (Becton Dickinson, Sparks, MD), 20 g NaCl, and 10 g
Bacto® Yeast Extract (Becton Dickinson) in 1940 mL water. The solution was adjusted
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to pH 7.0. The broth was autoclaved on a liquid cycle for 45 min and allowed to cool.
Ampicillin (amp) stock solution (100 mg/mL) was made by dissolving 1000 mg
ampicillin sodium salt (Fisher, Fairlawn, NJ) in 10 mL of sterile water. Ampicillin stock
solution (2 mL) was added to the 2 L sterile broth. The resultant solution (2 L LB + 2 mL
amp broth) was stored at 4 °C.
A second complete protocol was performed as above except that 3 L of broth was
made with 30 g BactoTM Tryptone (Becton Dickinson, Sparks, MD), 30 g NaCl, and 15 g
Bacto® Yeast Extract (Becton Dickinson) in 2910 mL water with 3 mL amp broth.

Inoculation of LB media and the growth of H229A. From the 2 L of LB + 2 mL amp
broth, 100 mL were transferred to each of the two 125 mL Erlenmeyer flasks. A loop of
mutant H229A was transferred into each flask. The broth was stirred with the same
inoculating loop. The cryovial containing H229A was immediately put back into the -80
°C freezer. Both flasks were covered with slightly loosened aluminum foil that allowed
air to circulate and were incubated for 16 h at 37 °C with shaking at 200 rpm. The broth
had an OD660 of approximately 1. The remaining LB media was divided into two 3000
mL Erlenmeyer flasks (~900 mL each). To each flask, 100 mL inoculated broth with
H229A was added. Two 3000 mL flasks were again placed in the shaker for 3 h at 37 °C
with 200 rpm.
A 2.0% arabinose stock solution was prepared by diluting 4 g of L-arabinose
(Acros Organics, Morris Plains, NJ) in 200 mL of water. The solution was vortexed to
dissolve the solid and filtered through a 0.20 µm MF75 Nalgene filter unit (Nalgene
Labware, Rochester, NY).
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After 3 h of shaking, arabinose stock solution (0.05 mL) was added to each flask. The
flasks continued to inoculate at 37 °C with shaking at 200 rpm for 4 h.
Similar to the first run, a second complete protocol was performed as above
except that 100 mL were transferred to each of the three 125 mL Erlenmeyer flasks.
After 16 h of incubation, the growth media was cloudy and had an OD660 of
approximately 2.8 (using LB broth as a baseline). The remaining LB media was divided
into three 2800 mL Erlenmeyer flasks (~900 mL each). To each flask, 125 mL
inoculated broth with H229A was added. Three 2800 mL flasks were again placed in the
shaker for 3 h at 37 °C with 200 rpm. After 3 h of shaking, the growth media had an
OD660 of approximately 2.5. The arabinose stock solution (5.0 mL) was added to each
flask. The flasks continued to inoculate at 37 °C with shaking at 200 rpm for 4 h. The
growth media had an OD660 of approximately 5.

Centrifugation. The inoculated sample was transferred to eight sterile plastic centrifuge
bottles and centrifuged at 8000 x g for 10 min at 4 °C (Eppendorf Centrifuge 5804 R).
The supernatant was discarded. The collecting pellets were placed in cryogenic vials and
stored in the freezer at
-20 °C.

French press procedure. Extraction buffer was prepared by dissolving 2.42 g of 20 mM
Tris (Fisher Chemicals, Fair Lawn, NJ), 5.84 g of 100 mM NaCl (Aldrich Chemical
Company, Milwaukee, WI), and 1 mL of neat 0.1% Triton (MP Biomedicals) in 1 L
water to give a buffer solution of 50 mM Tris. The extraction buffer was adjusted to pH
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8.0 using HCl. To each of three falcon tubes, two Complete Mini EDTA-free protease
inhibitor tablets (Roche Diagnostics, Indianapolis, IN) were dissolved in 30 mL of
extraction buffer. Each tube was vortexed until the tablet was dissolved. The solutions
were allowed to stand until the bubbles had dissipated. Approximately 9 g of cell pellets
were diluted 1:10 by mixing with extraction buffer at 4 °C. This solution was divided
equally onto the three falcon tubes and mixed with extraction buffer by vortexing. The
falcon tubes were placed on ice. Using a SIM-AMINCO Spectronic Instruments French
R Pressure Cell Press, each faction was French pressed at a setting of 1200-1280 on the
high ratio unit. Each drop was collected in a falcon tube on ice. Each sample was French
pressed twice. The samples were centrifuged at 12000 x g for 10 min. The 90 mL of
supernatants were collected and the pellets were discarded. Supernatants were
concentrated to 35 mL using 15 mL cellulose 5,000 MWCO tube in an Amicon Ultra
centrifugal filter device (Millipore, Billerica, MA).
A second complete protocol was carried out as above except that 100 mL of
glycerol (Fisher Scientific, Fair Lawn, NJ) was added into the extraction buffer to make
50 mM Tris plus 10% glycerol. To each of two falcon tubes, two Complete Mini EDTAfree protease inhibitor tablets (Roche Diagnostics, Indianapolis, IN) were dissolved in 45
mL of extraction buffer. Each tube was vortexed until the tablets were dissolved. The
solutions were allowed to stand until the bubbles had dissipated. Approximately 5 mL of
cell pellets were added into each of the falcon tube and mixed by vortexing. The falcon
tubes then placed on ice. Using a SIM-AMINCO Spectronic Instruments French R
Pressure Cell Press, each faction was French pressed at a setting of 1200-1280 on the
high ratio unit. The output was collected in two falcon tubes on ice. These samples were

19
treated again with the French press and the output collected as second time. The samples
were centrifuged at 20,000 x g for 25 min. The supernatants (~100 mL) were collected
and syringe filtered using a sterile Millex-HV Syringe Driven filter unit with 0.45 μm
PVDF filter (Millipore, Bedford, MA) into three falcon tubes. One of these tubes was
used for nickel affinity purification (below) and the other two were stored at -80 oC. The
pellets were discarded.

Nickel affinity fast protein liquid chromatography (FPLC) preparation. Extraction
buffer (1 L) was prepared as described above. Binding buffer (buffer A) was prepared as
follows. K2HPO4 (87.09 g) was dissolved in a 500 mL volumetric flask of water.
KH2PO4 (68.05 g) was dissolved in a second 500 mL volumetric flask of water. The first
solution (80.2 mL) and the second solution (19.8 mL) were placed in a 2 L Pyrex bottle.
To this was added 29.22 g of NaCl and water added to make a 2 L solution. The pH was
adjusted to 7.4; and the solution was filtered by using a 0.45 µM pore size in a Nalgene
vacuum filter unit (Nalgene, Rochester, NY). The final solution was 50 mM potassium
phosphate with 250 mM NaCl at pH 7.4.
Buffer B (elution buffer) was prepared by diluting 68.08 g of 0.5 M imidazole in
1 L of Buffer A. The final solution (2 L) was vacuum filtered before use. Stripping
buffer (1 L) was prepared by adding 18.61 g of 0.05 M 2 Na-EDTA to 1 L of Buffer A.
The pH was made to 7.4, the solution was vacuum filtered before use. A 100 mL nickel
charging solution was prepared by adding 2.38 g of 0.1 M NiCl2 (Mallinckrodt Chemical
Works, St. Louis, MO) to a 100 mL volumetric flask and diluting with water to 100 mL.
The solution was vacuum filtered before use.
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A HiTrap® Chelating HP nickel column (GE Healthcare Bio-sciences) was
washed with 5-10 column volumes (1 CV = 5 mL) of water prior to charging to remove
any contaminants present. The column was washed with 5-10 CV of stripping buffer,
then at least 5-10 CV of binding buffer, and then 5-10 CV of water at 4.0 mL per min
with a pressure under 0.3 MPa. The column was charged with 4 CV of nickel charging
solution at 0.5 mL per min. The column was then washed with 5 CV of water and 5 CV
of binding buffer at 4.0 mL per min. Pump A, pump B, and the 5 mL column were
washed with water. The column was equilibrated with 5 CV binding buffer at 4.0 mL per
min. The 50 mL super loop was washed with water. The H229A sample was injected
into the super loop. Line A was placed into the binding buffer and line B was placed into
the elution buffer. The flow rate of the injection gradient elution was set at 0.2 mL per
min with the column pressure limit of 0.3 MPa. The fractions were collected in
disposable glass culture tubes. Fractions 1-9 and 15-30 were kept and the rest discarded.
After the run, the pumps were washed with water and then with 20% aqueous ethanol for
storage.
A second complete protocol was performed as above except that Buffer A and
Buffer B had 10% glycerol in each (a gift of Brian Sook, Georgia State University). For
this run, fractions 16-33 were kept and the rest discarded.
The sample from collected fractions was taken for UV-vis spectrum through using
cord cell. Buffer A was used for the baseline.

Gel electrophoresis. A 1.5 M Tris pH 8.8 buffer was made by dissolving 36.34 g Tris
(FisherBiotech, Fair Lawn, NJ) in water to make a 200 mL stock solution. The pH was
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adjusted to 8.8 using HCl. A 1.0 M Tris pH 6.8 buffer was prepared by diluting 11.11 g
Tris in water to make a 100 mL stock solution. The pH was adjusted to 6.8 using HCl.
The 10% sodium dodecyl sulfate (SDS) was made by mixing 1 g SDS (Fisher, Fair
Lawn, NJ) in 10 mL water. The 10% APS, ammonium persulfate, was prepared by
suspending 1 g ampicillin sodium salt (FisherBiotech, Fair Lawn, NJ) in 10 mL of water.
Two plates of 1.0 mm gels were made by preparing 15% resolving layer (bottom layer)
and 5% stacking layer (top layer). Resolving layer was prepared by dissolving 2.3 mL
water, 5.0 mL of 30% bisacrylamide (FisherBiotech, Fair Lawn, NJ), 2.5 mL of 1.5 M
Tris pH 8.8, 100 µL of 10% SDS, and100 µL of 10% APS. Immediately before putting
the gels solution into the gels maker, 4 µL TEMED (N,N,N’,N’-tetra-methylethylenediamine, Bio-Rad Laboratories, Hercules, GA) was added onto the solution and
inverted five times to mix. The gel solution was filled up to 2/3 of the plate. A 1 mL of
2-propanol (Fischer Chemicals, Fair Lawn, NJ) was added onto the gels maker. While
waiting for the resolving layer to solidify, a stacking layer was prepared by dissolving 6.8
mL water, 1.7 mL of 30% bisacrylamide, 1.25 mL of 1.0 M Tris pH 6.8, 100 µL of 10%
SDS, and 100 µL of 10% APS. When the resolving layer had solidified, water was used
to remove the 2-propanol. Filter paper was used to remove the water. TEMED (10 µL)
was added to the stacking solution and inverted five times to mix. The solution was then
added onto the top of the resolving layer. The 1.0 mm comb was added to the gel maker
to make lanes. After the gels had solidified, both gels were washed with water under
light pressure, wrapped with moisture paper towels, and kept in the refrigerator at 4 °C.
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SDS-PAGE of nickel affinity FPLC fractions. The gels were loaded into a Mini
PROTEAN® 3 Cell (Bio-Rad). A 500 mL running buffer at pH 8.3 was prepared by
diluting 50 mL of 10 X Tris-glycine-SDS buffer (Fisher cat. BP1341-1) with 450 mL
water. The running buffer was poured into the Mini PROTEAN® 3 Cell. Mixed
Laemmli sample buffer was made by adding 50 μL 2-mercaptoethanol (Bio-Rad) with
450 μL of Laemmli sample buffer (Bio-Rad). A 5 μL sample was taken from each of the
affinity FPLC fractions 4, 6, 16, 17, 18, 21, 23, 25, 27, and 28. Each of these was mixed
with 10 μL of mixed Laemmli sample buffer. Samples were centrifuged for 15 sec on a
VWR mini-centrifuge C-1200 and heated for 5 min at 103°C. Five μL of Precision Plus
Protein® molecular weight marker standard (Bio-Rad) were added to lane one. Heated
samples were loaded into the remaining gel lanes. The gel was run at 60 – 80 V until the
blue Laemmli sample buffer band was 1 cm below the lanes, at which point the voltage
was increased to 100 – 120 V until the dye reached the bottom of the gel.
Destaining solution was made by combing 5 parts methanol (Fisher) to 1 part
glacial acetic acid (EMD Chemicals, Gibbstown, NJ) and 4 parts water. A Coomassie®
Blue staining solution was prepared by dissolving 0.25 g of Coomassie® Brilliant Blue
R-250 (Bio-Rad, Hercules, CA) into 100 mL of destaining solution. The gels were
removed and stained in the staining solution for 30 min and destained for 2 h on a rotary
shaker. The gels were washed with deionized water three times for two min each. The
water was emptied and Gel-DryTM Drying solution (Invitrogen, Carlsbad, CA) was added.
The gel was equilibrated by shaking the gel for 20 min in the StainEaseR Gel Staining
Tray. The gel was removed and placed between two celloplane sheets.
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A second complete protocol was performed as above except that mixed Laemmli
sample buffer was made by adding 25 μL 2-mercaptoethanol (Bio-Rad) with 475 μL of
Laemmli sample buffer (Bio-Rad). A 5 μL sample was taken from each of the affinity
FPLC fractions 18, 19, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and 35.
The gels were removed and stained in the staining solution for 45 min and
destained overnight (approximately 12 h) on a rotary shaker.

Exchanging imidazole buffer into 10 mM Tris pH 8 to remove salt for anion
exchange FPLC. A solution of 10 mM Tris pH 8.0 was prepared by dissolving 10 mL of
1 M Tris Buffer pH 8 stock solution (FisherBiotech, Fair Lawn, NJ) in 990 mL of water
and the pH adjusted to 8.0. The solution was filtered using a 0.45 µM pore size
surfactant free cellulose acetate membrane in a Nalgene vacuum filter unit (Nalgene,
Rochester, NY). Fractions 25 through 31 from the first run of the nickel affinity FPLC
were combined and placed into three Amicon Ultra 15 filter units with a 5,000 MWCO
Ultracel membrane (Millipore, Billerica, MA). The tubes were centrifuged at 5000 x g for
15 min at 4°C. Approximately 5 ml of 10 mM Tris was added to the remaining protein
solution in each tube and the tubes were centrifuged in the same manner again. This
process was repeated 4 times and yielded a total of 4.5 mL of a solution of protein in 10
mM Tris pH 8.

Anion exchange FPLC. Starting buffer was prepared by adding 10 mL 1 M Tris
(Fisher, Fair Lawn, NJ) to 990 mL of water. The solution was filtered as described above
and adjusted to pH 8.0 by adding HCl. Elution buffer was made by mixing 500 mL of
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start buffer with 500 mL of 1 M NaCl (which was prepared by diluting 29.22 g of NaCl
in 500 mL of water). The solution was filter and adjusted to pH 8.0 as described above.
The FPLC was fitted with a HiTrapTM Q HP 5 mL (GE Healthcare Bio-sciences)
column and washed with water. Pumps A and B were also washed with water. The
column was washed with ten CV of anion exchange start buffer (10 mM Tris-HCl pH
8.0), five CV of anion exchange elution buffer (anion exchange start buffer and 1.0 M
NaCl), and then equilibrated with seven CV of anion exchange start buffer. The 4.5 mL
protein solution was loaded into the superloop and injected into the column. Elution of
the protein was performed by running five CV of anion exchange start buffer through the
column followed with a 10 CV linear gradient. The gradient began with 100% anion
exchange start buffer and ended with 100% anion exchange elution buffer. Fractions 6 to
11 were collected.

Exchanging imidazole buffer to water for mass spectrometry. From second run,
fraction 32 (25 μL) was placed in a Microcon Utracel YM-3 filter unit with 3,000
MWCO (Millipore, Bedford, MA). The sample was centrifuged at 3000 x g for 45 min at
4°C. The sample was centrifuged for additional 20 min until the sample was reduced to
10 μL. Water (20 μL) was added onto the sample which was centrifuged for 45 min. The
process was repeated ten times. ESI and MALDI mass spectra were taken; the sample
still contained too much salt.
A second protocol was performed as above except that the sample (20 μL) was
centrifuged at 1400 x g for 45 min. This process repeated twice until the sample dropped
to 7 μL. Water (30 μL) was added and centrifuged two times for 60 min each. Another
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20 μL water was added and centrifuged 60 min. This step was repeated a second time.
ESI and MALDI mass spectra were taken. The former was not successful; data for the
latter are shown.

SiaA thermal stability: Initial practice on myoglobin. Phosphate buffer (50 mL) was
prepared by mixing 2.5 mL of KH2PO4 with 3.97 mL of K2HPO4 in a falcon tube, and
making the solution up to 50 mL. A sample of myoglobin (100.0 µL solution of
myoglobin in 10 mM Tris pH 8.0 was diluted in 1.00 mL of phosphate buffer) from
equine skeletal muscle (Sigma, St. Louis, MO) was placed in the UV cuvette, and
absorbance reading at room temperature was taken. The temperature was then raised to
30 ºC and the absorbance was recorded. After one hour, the absorbance was recorded
again. The UV spectrum was retaken after another h. The temperature was increased by
another 10 ºC and a spectrum was taken. The absorbance was recorded again after one
and two h. This process was continued in temperature increments of 10 ºC until the
temperature reached 70 ºC. The myoglobin cuvette then sat at room temperature
overnight. The absorbance was recorded. The temperature was then raised directly to 70
ºC. Uv-vis spectra were taken after about five minutes and again after 1 h.

SiaA thermal denaturation: Initial practice on myoglobin. Myoglobin was dissolved
in the 50 mM pH 7.5 M buffer (discussed above under the nickel affinity column) to give
an OD409 of approximately 0.1 and the pH adjusted down to 7.1 by adding dilute HCl.
The height of the sample inside the cuvette was measured.
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Using the ADL shell of the Varian-Cary, the temperature was programmed to
start at 25 °C and end at 95 °C. A 5 min equilibration time was added at the start of the
run. The temperature was increased at 0.5 °C per min with a signal averaging time of 0.5
sec. The wavelength was 409 nm. When temperature reached 95 °C, the sample was
removed and a blank buffer solution was re-measured. The sample was allowed to cool
down to room temperature. The absorbance was re-recorded from 250 to 700 nm. The
sample pH and its height were re-measured.
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Results and Discussion:

Homologous structure. The sequence of wild type SiaA (Figure 6) was submitted to
3D-JIGSAW, which searches the Protein Database (PDB) for homologous proteins.
BtuF (1N4D) was returned by the program at the most homologous structure (Figure 7).
The hypothetical 3D structure of wild type SiaA was created and allowed us to see the
possible heme ligands included Met79, Tyr63, Tyr179, and His229. The LOOPP program
gave three homologous structures, BtuF, CeuE, and FhuD (Figures 8, 9, and 10). In all
three cases, Met79 and His229 were in position to be possible axial ligands. The
structure of CeuE threaded into SiaA showed that Met79 and His229 were close to one
another, and in excellent positions to bind heme.
Although the results of both JIGSAW and LOOPP did not included IsdE as a
homologous structure, position specific iterative Blast (PSI-Blast) and pattern hit initiated
Blast (PHI-Blast) both yielded IsdE at the most homologous structure to SiaA (Figure
11). SiaA and IsdeE sequences had 45% identical amino acids, 68% positives, and 0%
gaps. PSI-Blast and PHI-Blast showed that BtuF, FhuD, and CeuE had 20%, 25%, and
22% identities, and 45%, 43%, 42% positives, and 2%, 11%, 8% gaps, respectively, with
the SiaA sequence.
Homology modeling indicates that SiaA is made up mostly of α-helices. From
the homology modeling (Figure 7), it can be seen that Tyr179, Tyr63, His229, and Met79
are all possible ligands. We have proposed that SiaA binds heme through the axial
ligands His229 and Met79. It is also possible that histidine alone binds the heme. The
related Gram negative ShuT protein uses one tyrosine as an axial ligand, and has
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significant interaction with the second (Eakanunkul et al, 2005) so these are also
possibilities. Three additional axial ligand possibilities are Met/ Met, His/Tyr, and
Tyr/Tyr. However, few proteins containing Met/Met and His/Tyr axial ligands are
known, and there are no known proteins containing Tyr/Tyr (Dixon, unpublished).
Although His/His is a common ligand set, the two histidines are on the same side of the
heme in the homology modeling, and are thus not in position to both be axial ligands
simultaneously

Growth and isolation of H229A SiaA. Two fermentation runs (2 L and 3 L) of H229A
SiaA plasmid in E. coli were performed. The 2 L fermentation run gave approximately 9
g of cell pellets after centrifugation. The cell pellets were lysed using a French press. A
sample of 90 mL was collected and concentrated to 35 mL for purification by nickel
affinity FPLC.
Figure 12 shows the nickel affinity chromatogram. Fractions 1 to 9 are run
through. Fractions 15 to 24 show three peaks. Fractions 25 to 31 show one peak.
The UV spectra were taken for fractions 4, 6, 16, 17, 18, 21, 23, 25, 27, and 28
(Figure 13). Fractions 4 and 6 showed very strong bands at 280, indicating substantial
concentrations of protein in the flow through. No heme bands were seen as shown by the
absence of spectral intensity in the Soret region. The spectra of fractions 16, 17, 18, 21,
23 had shoulders at 420 nm, indicating the presence of heme proteins. The spectra of
fractions 25, 27, and 28 had peaks at 420 nm, indicating higher concentrations of
holoprotein.
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SDS-PAGE (not shown) of fractions 4, 6, 16, 17, 18, 21, 23, 25, 27, and 28 was
carried out. Fractions 4 and 6 showed clusters of bands. Fractions 16, 17, 18, 21, and 23
show many separated bands. Fractions 25, 27, and 29 show one strong band, with a
molecular weight appropriate for SiaA (Figure 14). Fractions 25 to 31 were combined
and exchanged into 10 mM Tris buffer, pH 8.0 to give a final sample of 4.5 mL.
Anion exchange purification was performed on this sample (Figures 15 and 16).
A series of 27 fractions were taken, with increasing concentrations of NaCl starting at
fraction 15. Three small peaks were seen. The computer reset itself after peak 27.
Figure 15 shows the subsequent fractions (labeling old fraction 28 as new fraction 1).
Again, three components were seen, eluting at 0.70 to 0.83 M NaCl. Samples were
colorless.
SDS-PAGE (not shown) of fractions 21, 22, 23, and 25 of the first chromatogram
and 7, 9, 10, and 11 of the second chromatogram was performed. No bands were seen.
All fractions were lost.
In the 3 L fermentation run, approximately 10 mL of cell pellets were collected
after centrifugation. The cell pellets were lysed using a French press and the eluate was
constantly kept on ice to prevent cleavage. A sample of 90 mL was collected; 45 mL was
used for purification by nickel affinity FPLC.
Figure 17 shows the nickel affinity chromatogram. Fractions 16 to 36 were
collected. Fractions 17 to 22 and 28 to 33 were colorless while fractions 23 – 27 were a
cloudy yellowish color. Fractions 16 to 27 showed one major peak while fraction 28 to
33 showed a smaller peak.
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The UV spectra were taken for fractions 17 to 22 (Figure 18) and 27 to 33 (Figure
19). All fractions showed bands at 280 and 420, indicating the presence of some apoand some holoprotein. The peak at 280 nm was larger than that at 420 nm indicating that
these were a mixture of apo- and holoprotein [pure holoprotein has a 420/280 ratio of
approximately 1.67 (Sook, unpublished)]. Figure 18 shows that the 420/280 nm ratio of
all the fractions was approximately 0.2-0.3, indicating that apo- and holoproteins were
not separating on the column.
A SDS-PAGE of the French pressed sample before chromatography and fractions
18, 19, 22 to 26, and 27 to 35 of the nickel affinity column was carried out (Figure 20 and
21). The French pressed sample showed a cluster of bands, indicating the presence of
multiple proteins. Fractions 18, 19, 22, and 24 also showed clusters of bands. Fractions
23 to 28 showed many separated lighter bands. Fractions 29 and 30 showed two bands
with that at the approximate molecular weight of the SiaA far darker than the low
molecular weight band. Fractions 31 to 32 showed one strong band while fractions 33 to
35 showed one lighter band.
From the SDS-PAGE, fractions 32 and 33 of the nickel affinity purification
appeared to be pure (Figure 22). Fraction 32 and 33 were selected for mass spectrometry.
The material was stored in the -80 oC freezer.

Mass spectrometry. Initial MALDI and ESI mass spectra of fraction 32 had a mass of
35441 Da. However, the spectrum had a number of peaks and was very noisy, indicating
substantial salt in the sample (Figures 23 and 24). The expected mass of the protein is
35421 Da (Figures 25, 26, and 27). Thus, the experimental peak was within 20 Da of the
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theoretical expectation (0.056%). For MALDI, it is expected that the mass error will be
less than 0.05% (18 Da in this instance). For ESI it is expected that the mass error will be
less than 0.02% (7 Da in this instance). After desalting, the MALDI mass spectrum
showed two peaks with molecular weights of 35386.6 Da and 35589.6 Da (Figures 28
and 29). Thus, one peak was too light by 34 Da and the other peak was too heavy by 169
Da. It was not known why desalting gave two peaks with masses that did not match the
theoretical mass.
A MALDI mass spectrum for fraction 33 was taken using carbonic anhydrase as
an internal standard (Figure 30). The sample had a mass of 35441 Da before desalting
and 35527 Da after desalting (Figure 31). Again, the peak appeared at higher mass after
desalting.
Before desalting, both fractions 32 and 33 had a mass of 35441 Da, which was
heavier than expected by 20 Da. The mass of 35441 is almost within the generally
accepted error of 0.05% from the expected mass of 35421 Da. Alternatively, the protein
may have bound a sodium ion. We had observed variable numbers of bound sodium ions
in previous spectra of SiaA from our laboratory. Replacement of a proton with a sodium
ion increases the mass of the protein by 22 Da. If the protein bound a sodium ion, the
experimental and theoretical masses were very close (35441 – Na = 35419 and 35421,
respectively).

Calculation of holoprotein. The experimental ratio of the peak at 409 nm to that at 280
nm was 0.25 ± 0.04, showing that the apo- and holoprotein did not separate on the
column (Figure 32). Approximately 15% of the protein was found in the holo form.
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Assuming an extinction coefficient of 1 x 105 M-1 cm-1 for the holoprotein at the Soret,
0.88 mg of holoprotein was isolated, indicating that the total amount isolated was 5.9 mg.

SiaA temperature stability. Studies of the temperature stability of SiaA were planned.
An initial practice run was performed with myoglobin to test the protocol (Figure 33 and
34). The UV-vis spectrum showed two peaks, at 280 (apo- and holoprotein) and 420
(holoprotein) nm. Myoglobin was stable up to 60 °C (Figure 33). The protein started to
denature, as shown by the shift in the position and intensity of the heme band, when the
temperature reached 70 °C (Figure 34).

SiaA thermal denaturation. To test the non-linear curve fitting program, the following
procedure was followed. First, a theoretical data set was created in Excel by assigning
numbers for the folded absorbance, folded slope, unfolded absorbance, unfolded slope,
enthalpy, and melting temperature. The expected extent of unfolding was calculated as a
function of temperature (Figure 35). These theoretical values were then fitted using
Kaleidagraph and the same equation. In general, one person created the theoretical data
and a second person fit the data.
Kaleidagraph fitted values for all variables were then compared with theoretical
values. Several trials and errors were carried out until Kaleidagraph values and
theoretical values matched. These trials helped solve programming errors.
It was desired to run a thermal denaturation of H229A SiaA. This sample was
15% holoprotein and 85% apo-protein. When the experiment was attempted, an increase,
rather than a decrease in absorbance was observed. The sample after heating was opaque.
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It was assumed that the apoprotein had denatured, leading to the opaqueness of the
sample.
It was hoped that it would be possible to perform a thermal denaturation of SiaA,
even with a substantial fraction of apoprotein, if the experiment could be done at a very
low absorbance of the holoprotein. It was desired to test a sample with an absorbance of
0.1 at 409 nm. A concentrated myoglobin sample was prepared with an OD409 of 1.041
(Figure 36). Appropriate dilutions gave a sample with an OD409 of 0.109 (Figure 34).
Denaturation was run by heating the sample from at 25 °C to 95 °C at 0.5 °C per
min (Figure 37). The sample had the pH 7.11 and a height of 3.5 cm before denaturation
and pH 7.19 and a height of 2.7 cm after denaturation. Over the course of the
experiment, the height of the sample decreased 0.8 cm and the pH increased by 0.09. The
sample had OD409 of 0.187 after denaturation (Figure 38). Evaporation of the sample
presumably led to an increase in concentration by a factor of 1.29. This increase in
concentration was presumably not linear over the course of the experiment, and therefore
was not taken into account in the data fitting.
Non-linear least squares fitting of the data to the relevant equation (Figure 35)
was performed with Kaleidagraph. Initially, one makes estimates of values for the six
relevant variables. These were, yn (m1) = 0.9, mn (m2) = -0.0001518 abs/°C, yu (m3) =
0.02125, mu (m4) = 0.0001086 abs/°C, ΔH (m5) = 10000 J, and Tm (m6) = 78 °C. A
series of input parameters with numerical values near these initial estimates were tried.
The final 10 fitting runs are shown in Figure 39. Various different sets of initial values
gave very similar sets of fitted parameters (Figure 40). The final error for each variable
was less than 1%. The melting point was 78.8 ± 0.1 °C and ΔH was 4611 ± 41 J. The
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melting point was consistent with previous findings of 75 °C by the Hildebrand group
(Hildebrand et al., 1995).
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Conclusions

In this work, the H229 mutant of the heme binding protein SiaA was isolated.
Growth of the organism, followed by French press to lyse the cells, and nickel affinity
FPLC, gave the desired protein. SDS-PAGE showed that pure H229A was isolated.
Both ESI and MALDI mass spectrometry indicated a mass of 35441 Da, very close to the
expected value of 35421 Da. The protein may bind a sodium ion in the gas phase.
Histidine 229 is likely to be an axial ligand in wild type SiaA; the mutant readily lost
heme as evidenced by UV-visible spectra. Calculations indicated that the protein was
about 15% holo and 85% apo as isolated. The assignment of H229 as the axial ligand is
also consistent with computer threading studies of the structure with related proteins
which bind heme, vitamin B12 and iron. Preliminary studies on thermal denaturation of
heme proteins were performed.
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Figure 1. Streptococcal iron acquisition gene cluster.
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Xpress epitope
6x His tag
EK
SiaA

MGGSHHHHHHGMASMTGGQQMGRDLYDDDDKDR-WGSELE

Figure 2. The SiaA construct (Bates et al, 2005). The black band is the lipoprotein that
was replaced with His-Tag (blue), Xpress epitope (green), and enterokinase (EK) (green)
cleavage site, and additional residues (red). The orange sequence shows the observed
alternative EK cleavage site.
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Figure 3. Representative diagram of Sia ABC. SiaA, bound to the plasma membrane,
binds heme and carries it to SiaB, the permease, which transports heme to the inner
membrane through SiaC, the ATPase system.

42

Figure 4. B12-bound BtuF associating with BtuC2D2. Reprinted from (Locher et al,
2004).
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Figure 5. An Isd system model displaying the cell wall linked proteins, IsdABCH, the
transporter, IsdDEF, and the cytosolic proteins IsdGH. Reprinted from (Skaar et al,
2004).
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1
41
81
121
161
201
241
281

MIKRCKGIGL
VAVVDICDRL
PDIELIASLK
RSVEGMYQSI
RKGKKKPKVL
YQSDEKEFLS
KEFAENDIWK
DTLTQLFDHV

ALMAFFLVAC
NLDLVGVCDS
PTWILSPNSL
DDLGNLFQRQ
ILMGLPGSYL
ANPEDMLAKE
HFTAVKEGKV
GDHP

VNQHPKTAKE
KLYTLPKRYD
QEDLEPKYQK
QEAKELRQQY
VATNQSYVGN
PDLILRTAHA
YDLDNTLFGM

TEQQRIVATS
AVKRVGLPMN
LDTEYGFLNL
QDYYRAFQAK
LLDLAGGENV
IPDKVKVMFD
SAKLNYPEAL

MGGSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQHPKTAKET
EQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRYDAVKRVGLPMNPDIELI
ASLKPTWILSPNSLQEDLEPKYQKLDTEYGFLNLRSVEGMYQSIDDLGNLFQRQQ
EAKELRQQYQDYYRAFQAKRKGKKKPKVLILMGLPGSYLVATNQSYVGNLLDL
AGGENVYQSDEKEFLSANPEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDI
WKHFTAVKEGKVYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGDHP]]

Figure 6. (Top) The sequence of wild type SiaA (Bates et al, 2005). (Bottom) The
recombinant SiaA sequence (Bates et al, 2005). Enterokinase is expected to cleave at the
red bracket (after DDDDK). However, experiments showed that EK cleaved at both
brackets. The molecular weight of the entire construct is 35,618. Within the red
brackets, the apoprotein weighs 31,918 while the holoprotein weighs 32,534. For the
black brackets, the apoprotein weighs 32,189 while the holoprotein weighs 32,805. The
blue sequence at the N-terminus contains a His-Tag and Xpress epitope.
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Tyr179
Tyr179

His229

Tyr63

Met79

Figure 7. Wild type SiaA was threaded into 1N4D (BtuF ligand unbound) (Karpowich
et al, 2003). The His229, Met79, Tyr63, and Tyr179 residues are colored red, blue,
yellow and yellow, respectively, and displayed using space filling models. Data are from
3D-Jigsaw, visualized with RasMol 2.7.2.2.1.

46

Figure 8. Wild type SiaA was threaded into 1N4A (BtuF ligand unbound) (Karpowich
et al, 2003). The proposed His229 and Met79 residues are showed in red and blue,
respectively. Data are from LOOPP, visualized with RasMol 2.7.2.2.1.
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Figure 9. Wild type SiaA was threaded into 2CHU (CeuE ligand unbound) (Muller et
al, 2006). The proposed His229 and Met79 residues are showed in red and blue
respectively. Data are from LOOPP, visualized with RasMol 2.7.2.2.1.
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Figure 10. Wild type SiaA was threaded into 1K7S (FhuD ligand unbound) (Clarke et
al, 2002a). The proposed His229 and Met79 residues are showed in red and blue
respectively. Data are from LOOPP, visualized with RasMol 2.7.2.2.1.
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PDB ID
2Q8Q
2QI9
1EFD
2CHU

Name
IsdE
BtuF
FhuD
CeuE

Identities (%)
45
20
25
22

Positives (%)
68
45
43
42

94
64
61
70
99

Gaps (%)
0
2
11
8

Figure 11. (Top) Sequence alignment between SiaA and IsdE, BtuF, CeuE, and FhuD
from PSI-Blast and PHI-Blast. (Bottom) Percent identities, positives, and gaps between
SiaA sequence and IsdE, BtuF, FhuD, and CeuE sequences. IsdE has highest percentage
of identities, positives, and lowest percentage of gap to SiaA.
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Figure 12. Nickel affinity FPLC chromatogram performed on French pressed,
centrifuged, and filtered supernatant from the 2 L run. The dotted line starting at fraction
10 indicates a linearly increasing concentration of elution buffer (binding buffer with 0.5
M imidazole). SiaA elutes at approximately 0.1 M imidazole. Fractions 15-31 were
collected.
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H229A UV-vis spectrum after FPLC PNI17 Nov.6-2006
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Figure 13. The UV-vis spectra of the fractions from Figure 11. The fraction with the
greatest amount of heme (420 nm) appears to be F28, indicating that the last of the peaks
eluted is the holoprotein.
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Figure 14. SDS-PAGE of nickel affinity FPLC fractions 16, 18, 21, 25, 26, 27, 29, 30,
and 31 from 2 L run (Figure 11). The MW lane contains the Precision Plus Protein®
molecular weight marker standard. Fractions 26, 27, and 29 show a solid band at
approximately 37 kDa.
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Figure 15. Anion exchange FPLC chromatogram using a HiTrap Q HP (5 mL) column
of fractions 25 to 31 from the nickel affinity purification. The green dotted line indicates
a linearly increasing concentration of NaCl in the elution buffer. The data was saved in
two files, fractions 1-27 and then (renumbering 28 as 1) fractions 1-14 (Figure 15). The
elution buffer started at fraction 15. Fractions 21, 23, and 25 (containing the three small
peaks) were collected.
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Figure 16. Anion exchange FPLC chromatogram using a HiTrap Q HP (5 mL) column
of fractions 25 to 31 from the nickel affinity purification. This is a continuation of data
from Figure 14. The green dotted line indicates a linearly increasing concentration of
NaCl in the elution buffer. The NaCl concentration at the start of the chromatogram was
0.4 M. The NaCl concentration in the elution buffer was 1.0 M. The peak at 30.85 min
eluted at 0.77 M NaCl.
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Figure 17. Nickel affinity FPLC chromatogram performed on French pressed,
centrifuged, and filtered supernatant from the 3 L run. The dotted line starting at fraction
11 indicates a linearly increasing concentration of elution buffer (binding buffer with 0.5
M imidazole). SiaA is found in fractions 28 – 34. It elutes at approximately 0.12 M
imidazole. Fractions 15 - 35 were collected.
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H229A FPLC Ni Affinity F17-22 PNI34 3-15-2007
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Figure 18. The spectra of fractions 17-22 from the nickel affinity column in Figure 16.
The leading edge of the peak has heme; the trailing edge does not appear to contain
heme. SDS PAGE (Figure 19) shows that these fractions have a number of proteins.
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H229A FPLC Ni Affinity F28-33 PNI34 3-15-2007
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Figure 19. The spectra of fractions 27 – 33. The peaks at 420 nm showed that these
fractions contain holoprotein. The fact that the peak at 280 nm is larger than that at 420
nm indicates that these are a mixture of apo- and holoprotein (pure holoprotein has a
420/280 ratio of approximately 1.67 (Sook, unpublished). The fact that the 420/280 ratio
of all the fractions is approximately 0.21 to 0.30 indicates that the apo- and holoproteins
are not separating on the column.
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Figure 20. SDS-PAGE of nickel affinity FPLC fractions 18, 19, 22, 23, 24, 25, and 26
from 3 L run (Figure 16). The MW lane contains the Precision Plus Protein® molecular
weight marker standard. All fractions contained some contaminant proteins; fractions 23,
25, and 26 are the purest.
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Figure 21. SDS-PAGE of nickel affinity FPLC fractions 27 to 35 from the 3 L run
(Figure 16). The MW lane contains the Precision Plus Protein® molecular weight
marker standard. Fractions 30, 31, and 32 showed one solid band.
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Figure 22. SDS-PAGE of nickel affinity FPLC fractions 32 and 33 from the 3 L run
(Figure 16). The MW lane contains the Precision Plus Protein® molecular weight
marker standard. Fractions 32 and 33 showed one solid band.
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Figure 23. MALDI mass spectrum of fraction 32 from Figure 20. The tallest peak is at
35441 Da. The spectrum indicates that the sample is very salty.
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Figure 24. ESI mass spectrometry of fraction 32 from Figure 20. The tallest peak is at
35441.0 Da. The spectrum indicates that the sample is very salty.

63

Wild type (WT) SiaA Sequence

Molecular
Weight (Da)

MGGSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQ
HPKTAKETEQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRY 35618.2
DAVKRVGLPMNPDIELIASLKPTWILSPNSLQEDLEPKYQKLDTEYG
FLNLRSVEGMYQSIDDLGNLFQRQQEAKELRQQYQDYYRAFQAKR
KGKKKPKVLILMGLPGSYLVATNQSYVGNLLDLAGGENVYQSDEK
EFLSANPEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDIWKHFT
AVKEGKVYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGDHP]]
_GGSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQ
HPKTAKETEQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRY 35487.0
DAVKRVGLPMNPDIELIASLKPTWILSPNSLQEDLEPKYQKLDTEYG
FLNLRSVEGMYQSIDDLGNLFQRQQEAKELRQQYQDYYRAFQAKR
KGKKKPKVLILMGLPGSYLVATNQSYVGNLLDLAGGENVYQSDEK
EFLSANPEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDIWKHFT
AVKEGKVYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGDHP]]
__GSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQ
HPKTAKETEQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRY 35430.0
DAVKRVGLPMNPDIELIASLKPTWILSPNSLQEDLEPKYQKLDTEYG
FLNLRSVEGMYQSIDDLGNLFQRQQEAKELRQQYQDYYRAFQAKR
KGKKKPKVLILMGLPGSYLVATNQSYVGNLLDLAGGENVYQSDEK
EFLSANPEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDIWKHFT
AVKEGKVYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGDHP]]
MGGSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQ
HPKTAKETEQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRY 35521.1
DAVKRVGLPMNPDIELIASLKPTWILSPNSLQEDLEPKYQKLDTEYG
FLNLRSVEGMYQSIDDLGNLFQRQQEAKELRQQYQDYYRAFQAKR
KGKKKPKVLILMGLPGSYLVATNQSYVGNLLDLAGGENVYQSDEK
EFLSANPEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDIWKHFT
AVKEGKVYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGDH_]]
_GGSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQ
HPKTAKETEQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRY 35389.9
DAVKRVGLPMNPDIELIASLKPTWILSPNSLQEDLEPKYQKLDTEYG
FLNLRSVEGMYQSIDDLGNLFQRQQEAKELRQQYQDYYRAFQAKR
KGKKKPKVLILMGLPGSYLVATNQSYVGNLLDLAGGENVYQSDEK
EFLSANPEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDIWKHFT
AVKEGKVYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGD_]]
Figure 25: The molecular weight of WT SiaA, SiaA – Met, SiaA – (Met + Gly), SiaA –
Pro, and SiaA – (Met + Pro).
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Mutant SiaA (H229A) Sequence

Molecular
Weight (Da)

MGGSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQ
HPKTAKETEQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRYD 35552.2
AVKRVGLPMNPDIELIASLKPTWILSPNSLQEDLEPKYQKLDTEYGFL
NLRSVEGMYQSIDDLGNLFQRQQEAKELRQQYQDYYRAFQAKRKGK
KKPKVLILMGLPGSYLVATNQSYVGNLLDLAGGENVYQSDEKEFLSA
NPEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDIWKHFTAVKEG
KVYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGDAP]]
_GGSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQH
PKTAKETEQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRYDA 35421.0
VKRVGLPMNPDIELIASLKPTWILSPNSLQEDLEPKYQKLDTEYGFLN
LRSVEGMYQSIDDLGNLFQRQQEAKELRQQYQDYYRAFQAKRKGKK
KPKVLILMGLPGSYLVATNQSYVGNLLDLAGGENVYQSDEKEFLSAN
PEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDIWKHFTAVKEGK
VYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGDAP]]
__GSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQH
PKTAKETEQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRYDA 35363.9
VKRVGLPMNPDIELIASLKPTWILSPNSLQEDLEPKYQKLDTEYGFLN
LRSVEGMYQSIDDLGNLFQRQQEAKELRQQYQDYYRAFQAKRKGKK
KPKVLILMGLPGSYLVATNQSYVGNLLDLAGGENVYQSDEKEFLSAN
PEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDIWKHFTAVKEGK
VYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGDAP]]
MGGSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQ
HPKTAKETEQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRYD 35455.0
AVKRVGLPMNPDIELIASLKPTWILSPNSLQEDLEPKYQKLDTEYGFL
NLRSVEGMYQSIDDLGNLFQRQQEAKELRQQYQDYYRAFQAKRKGK
KKPKVLILMGLPGSYLVATNQSYVGNLLDLAGGENVYQSDEKEFLSA
NPEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDIWKHFTAVKEG
KVYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGDA_]]
_GGSHHHHHHGMASMTGGQQMGRDLYDDDDK[DR[WGSELEVNQH
PKTAKETEQQRIVATSVAVVDICDRLNLDLVGVCDSKLYTLPKRYDA 35323.8
VKRVGLPMNPDIELIASLKPTWILSPNSLQEDLEPKYQKLDTEYGFLN
LRSVEGMYQSIDDLGNLFQRQQEAKELRQQYQDYYRAFQAKRKGKK
KPKVLILMGLPGSYLVATNQSYVGNLLDLAGGENVYQSDEKEFLSAN
PEDMLAKEPDLILRTAHAIPDKVKVMFDKEFAENDIWKHFTAVKEGK
VYDLDNTLFGMSAKLNYPEALDTLTQLFDHVGDA_]]

Figure 26. The molecular weight of mutant SiaA, H229A – Met, H229A – (Met + Gly),
H229A – Pro, and H229A – (Met + Pro).
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Figure 27. The expected molecular weight (MW) of H229A is 35552.3 Da. The actual
MW of mutant SiaA (H229A – Met) is 35421 Da. The MW of fraction 33, H229A, is
35441 Da. It is heavier than the H229A – Met by 20 Da, which is close to the MW of a
sodium ion.
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Figure 28. MALDI mass spectrometry of fraction 32 after desalting. The tallest peaks
are at 35386.6 Da and 35589.6 Da. Both molecular weights are heavier than that
observed in the saltier sample (Figure 22). The theoretical weight of H229A SiaA is
35552.2.
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Figure 29. Close-up of the major peak from Figure 24.
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Figure 30. MALDI mass spectrum of fraction 33 from Figure 21. The tallest peak is at
35441 Da. Carbonic anhydrase was used for internal standard.
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Figure 31. MALDI mass spectrometry of fraction 33 after desalting. The tallest peak is
at 35526.5 Da. The molecular weight is heavier than the salting sample.
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Fraction
27
28
29
30
31
32
33

Abs

Abs

280 nm
0.55
0.55
0.65
0.85
0.89
0.73
0.57

409 nm
0.12
0.12
0.16
0.25
0.27
0.20
0.12
Avg
SD

Experimental
ratio
0.22
0.22
0.25
0.29
0.30
0.27
0.21
0.25
0.039

Fraction
holo
0.13
0.13
0.15
0.18
0.18
0.16
0.13
0.15

[Holo]
1.2E-06
1.2E-06
1.6E-06
2.5E-06
2.7E-06
2.0E-06
1.2E-06

grams
8.5E-05
8.5E-05
1.1E-04
1.8E-04
1.9E-04
1.4E-04
8.5E-05
8.8E-04

Assumes that each fraction is 2.0 mL,
that the extinction coefficient at the Soret is 1 x 105 M-1 cm-1
and the 409/280 nm ratio for holoprotein is 1.67
The expected molecular weight of the protein is 35,552.
Total protein 5.9 mg
Figure 32. Absorbances at 280 and 409 nm for fractions 27 - 33, allowing calculation of
the fraction of holoprotein, the molarity of holoprotein, and the weight of holoprotein for
each fraction. Totals are also given.
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M yoglobin temperature control I PN013 Sept. 25-2006
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Figure 33. Horse heart myoglobin in phosphate buffer as a function of temperature. The
temperature was held at each point for 2 h. The temperature was increased during the
run. The Soret band increases as the temperature increases up to 60 °C in this
experiment.
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Figure 34. Horse heart myoglobin in phosphate buffer as a function of temperature. The
temperature was held at each point for 2 h. The temperature was increased during the
run. When the sample was kept at 70 °C for 2 h, the Soret band decreased in intensity. A
further decrease was seen on heating to 80 °C.

73

yobs = (m1+m2*m0)+(m3+m4*m0)*(exp((m5/1.987)*((1/m6)-(1/m0))))
(1+exp((m5/1.987)*((1/m6)-(1/m0))))

Figure 35. (Top) Thermal denaturation equation (Swint & Robertson, 1993). (Bottom)
Thermal denature equation defined in Kaleidagraph. The experimental absorbance is
yobs. T (m0) is the temperature in Celsius; R is the gas constant (R = 1.987 (J/(mol*K));
ΔHm (m5) is the enthalpy; and Tm (m6) is the melting temperature. The y-intercepts of
the folded and unfolded baselines are yn (m1) and yd (m3), respectively. The slopes of
the baselines are mn (m2) and md (m4), respectively.
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Figure 36. Equine skeletal muscle myoglobin in phosphate buffer. At OD409, the
absorbance for the original sample, 1:3 dilution, and 1:0 dilution are 1.04, 0.34, and 0.11,
respectively.
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Figure 37. The absorbance at 409 nm of equine skeletal muscle myoglobin in 50 mM,
pH 7.1 phosphate buffer as a function of temperature.
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Figure 38. The absorbance of equine skeletal muscle myoglobin in 50 mM phosphate
buffer, pH 7.1 at room temperature after thermal denaturation.
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m1
(native)
Trial
1
2
3
4
5
6
7
8
9
10

(abs)
0.9
0.91
0.91
0.91
0.91
0.91
0.95
0.95
0.95
0.95
m1
(native)

Trials
1
2
3
4
5
6
7
8
9
10
AVG

(abs)

0.108
±5.466e-4
0.0951
±1.169e-4
0.0951
±1.169e-4
0.0951
±1.169e-4
0.0951
±1.169e-4
0.0951
±1.169e-4
0.0951
±1.169e-4
0.0951
±1.169e-4
0.0951
±1.169e-4
0.0951
±1.169e-4
0.0951
±1.169e-4

m2
(folding
slope)
(abs/°C)
-0.0001518
-0.0001518
-0.0001618
-0.0001718
-0.0001818
-0.0001818
-0.00018
-0.00018
-0.00018
-0.00018

m3
(unfolding)
(abs)
0.02125
0.02125
0.022
0.0225
0.03
0.015
0.01
0.005
0.0001
0

m2
(folding
slope)

m3
(unfolding)

(abs/°C)

(abs)

-0.000420
±1.067e-5
-0.000177
±2.401e-6
-0.000177
±2.401e-6
-0.000177
±2.401e-6
-0.000177
±2.401e-6
-0.000177
±2.401e-6
-0.000177
±2.401e-6
-0.000177
±2.401e-6
-0.000177
±2.401e-6
-0.000177
±2.401e-6
-0.000177
±2.401e-6

0.0238
±7.428e-3
-0.0320
±3.056e-3
-0.0320
±3.053e-3
-0.0320
±3.053e-3
-0.0322
±3.055e-3
-0.0322
±3.055e-3
-0.0320
±3.053e-3
-0.0320
±3.053e-3
-0.0320
±3.053e-3
-0.0320
±3.053e-3
-0.0321
±3.053e-3

m4
(unfolding
slope)
(abs/°C)
0.0001086
0.0001086
0.0001086
0.0001086
0.0001086
0.0001086
0.0001086
0.0001086
0.0001086
0.0001086
m4
(unfolding
slope)
(abs/°C)

0.0000510
±8.339e-5
0.000648
±3.311e-5
0.000648
±3.311e-5
0.000648
±3.311e-5
0.000650
±3.311e-5
0.000650
±3.314e-5
0.000648
±3.311e-5
0.000648
±3.311e-5
0.000648
±3.311e-5
0.000648
±3.311e-5
0.000649
±3.312e-5
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(ΔH)
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(°C)
78
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78.5
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78.8
78.8
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±41
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m6
(melting
temp)

R

(°C)

78.3
±0.05
78.8
±0.05
78.8
±0.05
78.8
±0.05
78.8
±0.05
78.8
±0.05
78.8
±0.05
78.8
±0.05
78.8
±0.05
78.8
±0.05
79 ±0.1

0.99052
0.99964
0.99964
0.99964
0.99964
0.99964
0.99964
0.99964
0.99964
0.99964
0.99964

Figure 39. Kaleidagraph data fitting. (Top) For each trial, the value for each variable
was estimated and put into thermal denaturation equation (Figure 37). The fitted values
are shown in the lower half of the table.
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Myoglobin Thermal Denaturation Trial 10 PNI49 Oct. 24-2007
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Figure 40. Kaleidagraph curve fit for Trial 10.
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